Treatment of systemic mast cell disorders.
The heterogeneous nature of disease manifestations in mastocytosis requires the individualization of therapy to each patient's clinical presentation and prognosis. The mainstay of treatment for most categories of mastocytosis are H1 and H2 antihistamines with the addition of corticosteroids for more severe symptoms. This article presents a summary of treatment strategies for indolent and aggressive forms of mastocytosis along with a discussion of future therapeutic directions.
Worobec
A S
AS
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. aworobec@niaid.nih.gov
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D018680:Cholinergic Antagonists; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D000075202:Contraindications; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D005483:Flushing / Q000188:drug therapy / Q000209:etiology; D005500:Follow-Up Studies; D006402:Hematologic Diseases / Q000150:complications / Q000628:therapy; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007946:Leukemia, Mast-Cell / Q000235:genetics / Q000628:therapy; D012515:Mast-Cell Sarcoma / Q000628:therapy; D008415:Mastocytosis / Q000145:classification / Q000150:complications / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D010024:Osteoporosis / Q000188:drug therapy / Q000209:etiology; D010778:Photochemotherapy; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics / Q000502:physiology; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000628:therapy; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000319:Adrenergic beta-Antagonists; D000970:Antineoplastic Agents; D018680:Cholinergic Antagonists; D004164:Diphosphonates; D006633:Histamine Antagonists; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D019009:Proto-Oncogene Proteins c-kit; D004205:Cromolyn Sodium; D001241:Aspirin